A Study to Evaluate the Safety and Effectiveness of Dupilumab and Milk Oral Immunotherapy to Treat Patients with Cow's Milk Allergy
Scottsdale/Phoenix, AZ
The purpose of this study is to assess whether dupilumab as an adjunct to milk oral immunotherapy (OIT) compared to placebo improves desensitization and safety, defined as an increase in the proportion of subjects who pass a double-blind placebocontrolled food challenge (DBPCFC) to at least 2040 mg cumulative milk protein at week 18.